The incidence of allergies is increasing, particularly in industrialized areas. Allergic inflammation can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Improving outcomes in severe paediatric asthma: New treatments, new possibilities
Watch an asthma expert and a primary care respiratory specialist discuss diagnosis, treatment and management of severe asthma in children.
- Recall the symptoms associated with severe asthma in children
- Summarize the clinical evidence supporting the use of biologics in children with severe asthma
- Describe the optimal long-term management of children with severe asthma
What’s new for eosinophilic oesophagitis? A case-based discussion of patient care
Watch experts give their perspective on different aspects of managing patients with EoE, based on clinical case studies.
- Describe the complex pathophysiology of EoE and how this manifests as clinical symptoms throughout life
- Distinguish eosinophilic oesophagitis as a progressive disease that is distinct from GORD
- Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
Watch leading experts discuss practical aspects of caring for children and adults with EoE, drawing on their own clinical experiences.
- Compare the pathophysiology and clinical manifestations of EoE between children and adults
- Summarize how the transition of care is managed as children with EoE become adults
- Evaluate the impact of the latest data for emerging biologic treatment options for EoE on clinical practice
Andreas Recke, EAACI 2022: Lanadelumab in the Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency
The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) to discuss the aims, design and findings from his interim analysis of the […]
Andreas Recke, EAACI 2022: Unmet Needs in the Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency
Hereditary angioedema with C1-inhibitor deficiency (HAE-C1-INH) is a rare disease resulting in unpredictable attacks of swelling under the skin. touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) around the health burden of HAE-C1-INH and the unmet needs in its treatment. The abstract ‘Lanadelumab Treatment Patterns Among Patients With HAE-C1-INH: Interim […]
Ana Maria Giménez-Arnau, EAACI 2022: A Phase 2b Study of Remibrutinib for Chronic Spontaneous Urticaria
Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic […]
Ana Maria Giménez-Arnau, EAACI 2022: Pathology and Unmet Needs in Chronic Spontaneous Urticaria
It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) to discuss the unmet needs in the treatment of chronic spontaneous urticaria and the rationale for investigating remibrutinib in this indication. The abstract ‘Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study […]
Exploring eosinophilic oesophagitis: How can multidisciplinary management improve outcomes?
Watch leading specialists involved in the multidisciplinary care of patients with eosinophilic oesophagitis address the optimal management of this disorder.
- Explain how the complex pathophysiology of eosinophilic oesophagitis (EoE) impacts diagnosis
- Assess the symptoms associated with EoE and the impact of this progressive disease on patients
- Evaluate how the emerging biologic treatment options for EoE may be incorporated into clinical practice
Improving outcomes for patients with eosinophilic oesophagitis: What do the data from AAAAI 2022 tell us?
Watch this two-part activity exploring recent data on eosinophilic oesophagitis from the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) 2022. Part 1: Watch leading gastroenterologist, Dr Evan Dellon, review key data from AAAAI 2022 Watch now Part 2: Hear from three leading experts in eosinophilic oesophagitis, as they discuss what these data may mean for global and regional practice Select an interview
- Summarize recent clinical evidence on the complex pathophysiology and manifestations of eosinophilic oesophagitis (EoE)
- Outline the chronic nature of EoE and the impact on patient quality of life
- Assess the latest data for emerging treatments for EoE and their impact on clinical practice
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!